Biobank for identifying biomarkers in lung cancer
Biobank for the Identification of Diagnostic, Prognostic or Therapeutic (Response and Resistance) Biomarkers in Lung Cancer (Early and Advanced Stages of Lung Cancer Cohort of the BIRD (Biomarkers in Respiratory Disease) Biobank)
This study is trying to find new ways to diagnose and treat lung cancer by collecting blood samples from patients at different stages of the disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Toulouse Academic / other |
| Locations | 1 site (Toulouse) |
| Trial ID | NCT06054854 on ClinicalTrials.gov |
What this trial studies
The BIRD biobank collects clinical and biological data from patients with chronic respiratory diseases, focusing on lung cancer. It divides participants into two cohorts: one for patients with early-stage lung cancer and another for those with advanced-stage lung cancer. The study aims to identify biomarkers through less invasive methods, such as blood samples, to improve diagnosis and treatment options. By analyzing these biomarkers, the research seeks to enhance screening and therapeutic strategies for lung cancer patients.
Who should consider this trial
Good fit: Ideal candidates include patients with lung nodules, suspected lung cancer, or confirmed lung cancer at various stages.
Not a fit: Patients who are pregnant or breastfeeding, or those deprived of liberty, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic and treatment options for lung cancer patients.
How similar studies have performed: Other studies have shown promise in identifying biomarkers through non-invasive methods, making this approach both relevant and potentially impactful.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with 1 to 3 lung nodules including one \> 1 cm seen on chest CT * OR: patients with suspected lung cancer requiring diagnostic and/or therapeutic bronchial endoscopy * OR: Patient with histologically confirmed lung cancer, whether early stages prior to surgery, locally advanced or metastatic, included before the start of any anti-cancer treatment. * Patient affiliated or beneficiary of a social security scheme * Patients who are able to receive and understand information about the study and their participation and who have freely given their signed inform consent before any collection of samples or data necessary for the research (no restriction of rights by the judicial authorities and knowledge of the French language). Exclusion Criteria: * Patient deprived of liberty on administrative or judicial decision, or patient under guardianship, curators or safeguard of justice * Female patients who are pregnant or breastfeeding
Where this trial is running
Toulouse
- Larrey Hospital — Toulouse, France (Recruiting)
Study contacts
- Principal investigator: Nicolas GUIBERT — University Hospital, Toulouse
- Study coordinator: Nicolas GUIBERT, MD PhD
- Email: guibert.n@chu-toulouse.fr
- Phone: +33567771836
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.